Annovis Bio announces the publication of patents covering the treatment of amyloid lateral sclerosis, Huntington’s disease and prion diseases

BERWYN, Pa., September 13, 2022 /PRNewswire/ — (NYSE: ANVS) Annovis Bio (“Annovis” or the “Company”), a clinical-stage pharmaceutical platform company treating neurodegenerative diseases, today announced the publication of three granted U.S. patents – US11400075 (link), US11376238 (link), and US11382893 (link). The patents cover methods of treating amyloid lateral sclerosis (ALS), Huntington’s disease and prion diseases by administering buntanetap. They will provide intellectual property protection until 2031, before any patent extension.

Patents strengthen and expand the Company’s intellectual property portfolio. The Company has now granted patents covering a wide range of neurodegenerative diseases, including Alzheimer’s disease (AD), alpha-synucleopathies, such as Parkinson’s disease (PD), tauopathies, such as frontotemporal dementia (FTD ), chronic traumatic encephalopathy (CTE) and acute injuries such as stroke and head trauma.

“These additional patents represent further evidence of our platform drug, buntanetap, which acts on a variety of neurodegenerative disorders by inhibiting several neurotoxic proteins,” said Maria L. Maccecchini, Ph.D., Founder, President and CEO of Annovis.

Summary of key coverage:

  • The invention relates to a method of treating amyloid lateral sclerosis, a rare progressive neurodegenerative disorder, by administering buntanetap and inhibiting the synthesis of protein superoxide dismutase1 and TDP43.
  • The invention relates to a method of treating Huntington’s disease, a rare progressive neurodegenerative disorder, by administering buntanetap and inhibiting huntingtin protein synthesis.
  • The invention relates to a method of treating prion diseases, a family of ultra-rare progressive neurodegenerative disorders, by administering buntanetap. There is additional coverage for certain prion diseases, including scrapie prion, transmissible mink encephalopathy (TME), chronic wasting disease (CWD), bovine spongiform encephalopathy (BSE) prion, feline spongiform encephalopathy (FSE), exotic ungulate encephalopathy (EUE), kuru prion, Creutzfeldt-Jakob disease (CJD), variant Creutzfeldt-Jakob disease (vCJD, nvCJD), Gerst-mann syndrome -Straussler-Scheinker (GSS) and Fatal Familial Insomnia (IFF) prion.

About Buntanetap

Buntanetap (formerly known as ANVS401 or Posiphen) is an oral translation inhibitor of neurotoxic aggregating proteins (TINAPs), whose mode of action leads to a lower level of neurotoxic proteins and consequently less toxicity in the brain. In a phase 2a clinical trial in patients with AD and PD, buntanetap was shown to be well tolerated and safe, and its pharmacokinetics were consistent with levels previously measured in humans, satisfying both primary and secondary endpoints. Additionally, exploratory endpoints were also met, as buntanetap treatment resulted in statistically significant improvement in motor function in patients with PD and cognition in patients with AD. Currently, buntanetap is in a Phase 3 study in early PD and will enter a Phase 2/3 study in patients with AD later this year.

About Anvis Bio, Inc.

Based at Berwyn, Pennsylvania, Annovis Bio, Inc. is a clinical-stage pharmaceutical platform company developing transformative therapies that treat neurodegenerative disorders such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and other diseases chronic and acute neurodegenerative diseases. The Company believes it is the only company to develop a drug that inhibits more than one neurotoxic protein, improves the nerve cell’s information highway, known as axonal transport, reduces inflammation and protects nerve cells against death in chronic and acute neurodegeneration. Annovis has conducted two phase 2 studies: one in patients with Alzheimer’s disease and one in patients with Alzheimer’s disease and Parkinson’s disease. In the AD/PD study, buntanetap showed improvements in cognition and memory in AD as well as body and brain function in patients with Parkinson’s disease.

For more information about Annovis Bio, please visit the company’s website and follow us on LinkedIn and Twitter.

Forward-looking statements

The statements in this press release contain “forward-looking statements” that are subject to substantial risks and uncertainties. Forward-looking statements in this press release can be identified by the use of words such as “anticipate”, “expect”, “believe”, “will”, “may”, “should”, “estimate”. , “project,” “outlook,” “forecast,” or other similar words, and include, but are not limited to, statements regarding the timing, effectiveness, and expected results of clinical trials of buntanetap. Forward-looking statements are based on Annovis Bio, Inc.’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. In addition, certain forward-looking statements are based on assumptions about future events which may not prove to be accurate. These and other risks and uncertainties are described in more detail in the section titled “Risk Factors” in the Annual Report on Form 10-K for the year ended. December 31, 2021, filed with the Securities and Exchange Commission. The forward-looking statements contained in this announcement are made as of this date, and Annovis Bio, Inc. assumes no obligation to update such information except as required by applicable law.

Media and investor contact:

Nic Johnson
Russo Partners, LLC
(303) 482-6405
[email protected]

Quote Show original content to download multimedia: 301622703.html

SOURCEAnnovis Bio

Jacob L. Thornton